Synaptogenix (NASDAQ:TAOX) Posts Quarterly Earnings Results

Synaptogenix (NASDAQ:TAOX) posted its earnings results on Wednesday. The company reported $0.43 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $5.96 million during the quarter.

Synaptogenix Stock Down 10.0%

NASDAQ:TAOX traded down $0.58 during mid-day trading on Friday, reaching $5.20. 97,806 shares of the company were exchanged, compared to its average volume of 171,416. Synaptogenix has a 12 month low of $2.12 and a 12 month high of $11.98. The company has a fifty day moving average of $5.38 and a 200 day moving average of $5.45. The stock has a market cap of $38.84 million, a PE ratio of -0.30 and a beta of 1.49.

Analyst Upgrades and Downgrades

TAOX has been the topic of several analyst reports. Wall Street Zen lowered shares of Synaptogenix from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.